These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 22477727)

  • 1. The European Medicines Agency review of cabazitaxel (Jevtana®) for the treatment of hormone-refractory metastatic prostate cancer: summary of the scientific assessment of the committee for medicinal products for human use.
    Pean E; Demolis P; Moreau A; Hemmings RJ; O'Connor D; Brown D; Shepard T; Abadie E; Pignatti F
    Oncologist; 2012; 17(4):543-9. PubMed ID: 22477727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Kearns B; Pandor A; Stevenson M; Hamilton J; Chambers D; Clowes M; Graham J; Kumar MS
    Pharmacoeconomics; 2017 Apr; 35(4):415-424. PubMed ID: 27770303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cabazitaxel for the second-line treatment of metastatic hormone-refractory prostate cancer: a NICE single technology appraisal.
    Kearns B; Lloyd Jones M; Stevenson M; Littlewood C
    Pharmacoeconomics; 2013 Jun; 31(6):479-88. PubMed ID: 23580356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cabazitaxel: a novel drug for hormone-refractory prostate cancer.
    Malhotra M; Dhingra R; Sharma T; Deep A; Narasimhan B; Phogat P; Sharma PC
    Mini Rev Med Chem; 2013 May; 13(6):915-20. PubMed ID: 22950608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer.
    Paller CJ; Antonarakis ES
    Drug Des Devel Ther; 2011 Mar; 5():117-24. PubMed ID: 21448449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cabazitaxel: a guide to its use in hormone-refractory metastatic prostate cancer.
    Keating GM
    Drugs Aging; 2013 May; 30(5):359-65. PubMed ID: 23532557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Critical appraisal of cabazitaxel in the management of advanced prostate cancer.
    Pal SK; Twardowski P; Sartor O
    Clin Interv Aging; 2010 Dec; 5():395-402. PubMed ID: 21152241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The European Medicines Agency review of ofatumumab (Arzerra®) for the treatment of chronic lymphocytic leukemia in patients refractory to fludarabine and alemtuzumab: summary of the scientific assessment of the European medicines agency committee for medicinal products for human use.
    Gravanis I; Ersbøll J; Skovlund E; Abadie E; Marty M; Pignatti F
    Oncologist; 2010; 15(12):1335-43. PubMed ID: 21156732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
    de Bono JS; Oudard S; Ozguroglu M; Hansen S; Machiels JP; Kocak I; Gravis G; Bodrogi I; Mackenzie MJ; Shen L; Roessner M; Gupta S; Sartor AO;
    Lancet; 2010 Oct; 376(9747):1147-54. PubMed ID: 20888992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cabazitaxel: a novel microtubule inhibitor.
    Villanueva C; Bazan F; Kim S; Demarchi M; Chaigneau L; Thiery-Vuillemin A; Nguyen T; Cals L; Dobi E; Pivot X
    Drugs; 2011 Jul; 71(10):1251-8. PubMed ID: 21770474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
    Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F
    Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The European medicines agency review of eribulin for the treatment of patients with locally advanced or metastatic breast cancer: summary of the scientific assessment of the committee for medicinal products for human use.
    Pean E; Klaar S; Berglund EG; Salmonson T; Borregaard J; Hofland KF; Ersbøll J; Abadie E; Giuliani R; Pignatti F
    Clin Cancer Res; 2012 Sep; 18(17):4491-7. PubMed ID: 22829199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cabazitaxel for the treatment of castration-resistant prostate cancer.
    Agarwal N; Sonpavde G; Sartor O
    Future Oncol; 2011 Jan; 7(1):15-24. PubMed ID: 21174534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The European Medicines Agency review of Tegafur/Gimeracil/Oteracil (Teysuno™) for the treatment of advanced gastric cancer when given in combination with cisplatin: summary of the Scientific Assessment of the Committee for medicinal products for human use (CHMP).
    Matt P; van Zwieten-Boot B; Calvo Rojas G; Ter Hofstede H; Garcia-Carbonero R; Camarero J; Abadie E; Pignatti F
    Oncologist; 2011; 16(10):1451-7. PubMed ID: 21963999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use.
    Hanaizi Z; Flores B; Hemmings R; Camarero J; Sancho-Lopez A; Salmonson T; Gisselbrecht C; Laane E; Pignatti F
    Oncologist; 2015 Mar; 20(3):329-34. PubMed ID: 25673103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The European Medicines Agency review of pixantrone for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphomas: summary of the scientific assessment of the committee for medicinal products for human use.
    Péan E; Flores B; Hudson I; Sjöberg J; Dunder K; Salmonson T; Gisselbrecht C; Laane E; Pignatti F
    Oncologist; 2013; 18(5):625-33. PubMed ID: 23615696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Managing side effects of the novel taxane cabazitaxel in castrate-resistant prostate cancer.
    Doyle-Lindrud S
    Clin J Oncol Nurs; 2012 Jun; 16(3):286-91. PubMed ID: 22641321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cabazitaxel for prostate cancer: patient preparation and ongoing care.
    Hardwick J
    Br J Nurs; 2012 May 10-23; 21(9):S13-7. PubMed ID: 22690408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The European Medicines Agency review of eltrombopag (Revolade) for the treatment of adult chronic immune (idiopathic) thrombocytopenic purpura: summary of the scientific assessment of the Committee for Medicinal Products for Human Use.
    Nieto M; Calvo G; Hudson I; Feldschreiber P; Brown D; Lee CC; Lay G; Valeri A; Abadie E; Thomas A; Pignatti F
    Haematologica; 2011 Sep; 96(9):e33-40. PubMed ID: 21712542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The European Medicines Agency Review of Decitabine (Dacogen) for the Treatment of Adult Patients With Acute Myeloid Leukemia: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
    Nieto M; Demolis P; Béhanzin E; Moreau A; Hudson I; Flores B; Stemplewski H; Salmonson T; Gisselbrecht C; Bowen D; Pignatti F
    Oncologist; 2016 Jun; 21(6):692-700. PubMed ID: 27091416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.